Evidence map›Paper›PMID 41087048›Full record

ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2025

Measles seroprevalence by birth cohort across the lifespan: a population-based, cross-sectional serosurvey in British Columbia, Canada.

Samantha E Kaweski, Lea Separovic, Samar Ashfaq, Y L Elaine Chan, Hadi Dalati, Bonnie Henry, Romina C Reyes, Joanne Hiebert, Danuta M Skowronski

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Samantha E KaweskiBC Centre for Disease Control, Immunization Programs and Vaccine Preventable Diseases Service (Kaweski, Separovic, Chan, Dalati, Skowronski), Vancouver, BC; Viral Diseases Division, National Microbiology Laboratory Branch (Ashfaq, Hiebert), Public Health Agency of Canada, Winnipeg, Man.; University of British Columbia, School of Population and Public Health (Henry, Skowronski), Vancouver, BC; Office of the Provincial Health Officer (Henry), Ministry of Health, Victoria, BC; University of British Columbia, Department of Pathology and Laboratory Medicine (Reyes), Vancouver, BC; LifeLabs (Reyes), Burnaby, BC.
Lea SeparovicBC Centre for Disease Control, Immunization Programs and Vaccine Preventable Diseases Service (Kaweski, Separovic, Chan, Dalati, Skowronski), Vancouver, BC; Viral Diseases Division, National Microbiology Laboratory Branch (Ashfaq, Hiebert), Public Health Agency of Canada, Winnipeg, Man.; University of British Columbia, School of Population and Public Health (Henry, Skowronski), Vancouver, BC; Office of the Provincial Health Officer (Henry), Ministry of Health, Victoria, BC; University of British Columbia, Department of Pathology and Laboratory Medicine (Reyes), Vancouver, BC; LifeLabs (Reyes), Burnaby, BC.
Samar AshfaqBC Centre for Disease Control, Immunization Programs and Vaccine Preventable Diseases Service (Kaweski, Separovic, Chan, Dalati, Skowronski), Vancouver, BC; Viral Diseases Division, National Microbiology Laboratory Branch (Ashfaq, Hiebert), Public Health Agency of Canada, Winnipeg, Man.; University of British Columbia, School of Population and Public Health (Henry, Skowronski), Vancouver, BC; Office of the Provincial Health Officer (Henry), Ministry of Health, Victoria, BC; University of British Columbia, Department of Pathology and Laboratory Medicine (Reyes), Vancouver, BC; LifeLabs (Reyes), Burnaby, BC.
Y L Elaine ChanBC Centre for Disease Control, Immunization Programs and Vaccine Preventable Diseases Service (Kaweski, Separovic, Chan, Dalati, Skowronski), Vancouver, BC; Viral Diseases Division, National Microbiology Laboratory Branch (Ashfaq, Hiebert), Public Health Agency of Canada, Winnipeg, Man.; University of British Columbia, School of Population and Public Health (Henry, Skowronski), Vancouver, BC; Office of the Provincial Health Officer (Henry), Ministry of Health, Victoria, BC; University of British Columbia, Department of Pathology and Laboratory Medicine (Reyes), Vancouver, BC; LifeLabs (Reyes), Burnaby, BC.
Hadi DalatiBC Centre for Disease Control, Immunization Programs and Vaccine Preventable Diseases Service (Kaweski, Separovic, Chan, Dalati, Skowronski), Vancouver, BC; Viral Diseases Division, National Microbiology Laboratory Branch (Ashfaq, Hiebert), Public Health Agency of Canada, Winnipeg, Man.; University of British Columbia, School of Population and Public Health (Henry, Skowronski), Vancouver, BC; Office of the Provincial Health Officer (Henry), Ministry of Health, Victoria, BC; University of British Columbia, Department of Pathology and Laboratory Medicine (Reyes), Vancouver, BC; LifeLabs (Reyes), Burnaby, BC.
Bonnie HenryBC Centre for Disease Control, Immunization Programs and Vaccine Preventable Diseases Service (Kaweski, Separovic, Chan, Dalati, Skowronski), Vancouver, BC; Viral Diseases Division, National Microbiology Laboratory Branch (Ashfaq, Hiebert), Public Health Agency of Canada, Winnipeg, Man.; University of British Columbia, School of Population and Public Health (Henry, Skowronski), Vancouver, BC; Office of the Provincial Health Officer (Henry), Ministry of Health, Victoria, BC; University of British Columbia, Department of Pathology and Laboratory Medicine (Reyes), Vancouver, BC; LifeLabs (Reyes), Burnaby, BC.
Romina C ReyesBC Centre for Disease Control, Immunization Programs and Vaccine Preventable Diseases Service (Kaweski, Separovic, Chan, Dalati, Skowronski), Vancouver, BC; Viral Diseases Division, National Microbiology Laboratory Branch (Ashfaq, Hiebert), Public Health Agency of Canada, Winnipeg, Man.; University of British Columbia, School of Population and Public Health (Henry, Skowronski), Vancouver, BC; Office of the Provincial Health Officer (Henry), Ministry of Health, Victoria, BC; University of British Columbia, Department of Pathology and Laboratory Medicine (Reyes), Vancouver, BC; LifeLabs (Reyes), Burnaby, BC.
Joanne HiebertBC Centre for Disease Control, Immunization Programs and Vaccine Preventable Diseases Service (Kaweski, Separovic, Chan, Dalati, Skowronski), Vancouver, BC; Viral Diseases Division, National Microbiology Laboratory Branch (Ashfaq, Hiebert), Public Health Agency of Canada, Winnipeg, Man.; University of British Columbia, School of Population and Public Health (Henry, Skowronski), Vancouver, BC; Office of the Provincial Health Officer (Henry), Ministry of Health, Victoria, BC; University of British Columbia, Department of Pathology and Laboratory Medicine (Reyes), Vancouver, BC; LifeLabs (Reyes), Burnaby, BC.
Danuta M SkowronskiBC Centre for Disease Control, Immunization Programs and Vaccine Preventable Diseases Service (Kaweski, Separovic, Chan, Dalati, Skowronski), Vancouver, BC; Viral Diseases Division, National Microbiology Laboratory Branch (Ashfaq, Hiebert), Public Health Agency of Canada, Winnipeg, Man.; University of British Columbia, School of Population and Public Health (Henry, Skowronski), Vancouver, BC; Office of the Provincial Health Officer (Henry), Ministry of Health, Victoria, BC; University of British Columbia, Department of Pathology and Laboratory Medicine (Reyes), Vancouver, BC; LifeLabs (Reyes), Burnaby, BC. danuta.skowronski@bccdc.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn 2025, the province of British Columbia (BC), Canada, experienced heightened measles activity, mostly involving unvaccinated communities. Publicly funded measles vaccination for children aged 12 months has been routine since 1969, with a second dose at age 18 months added in 1996, and rescheduled to 4 to 6 years (school entry) in 2012. We aimed to assess population-based measles seroprevalence in relation to historic measles endemicity and vaccination considerations.

methodsIn August 2024, we undertook a cross-sectional serosurvey, testing more than 1000 anonymized residual sera for measles antibody. We collected sera from outpatients attending a laboratory network in the Lower Mainland, BC, with equal numbers from 10 age groups, from 1 year to older than 80 years.

resultsMeasles seropositivity was 89% (95% confidence interval [CI] 87% to 91%) overall and 93% (95% CI 91% to 94%) if equivocal results were also considered positive. Seropositivity was 90% or higher in all age groups except 10- to 19-year-olds (82% [95% CI 74% to 89%]), 20- to 29-year-olds (69% [95% CI 59% to 78%]), and 30- to 39-year-olds (73% [95% CI 63% to 81%]). Results remained below 80% for 20- to 39-year-olds, and significantly below all other age groups, even considering equivocal results as positive. In birth cohort analysis, seropositivity appeared lower among those due for their second vaccine dose during the COVID-19 pandemic or born during the postvaccination era to mothers with a higher likelihood of previous infection when measles was endemic.

interpretationOur measles serosurvey findings inform vaccine coverage and complement other case-based surveillance indicating robust population-level immunity outside of unvaccinated clusters or communities. In addition to showing age-related antibody decline, serosurveillance provides insights into potential cohort effects that may have implications for vaccination programs.

Indexed as

MeaslesMeasles VaccineAdolescentAdultAgedAged, 80 and overAntibodies, ViralBirth CohortBritish ColumbiaChildChild, PreschoolCOVID-19Cross-Sectional StudiesFemaleHumansInfantAntibodies, ViralMeasles Vaccine

Identifiers

PMID41087048
PMCPMC12527300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.